About

Race Oncology is an ASX listed precision oncology company with a Phase II/III cancer drug called Zantrene

Zantrene® is a potent small molecule inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Over-production of FTO has been shown to be an important to the progression of a diverse range of cancers. Race Oncology is exploring the use of Zantrene® as a new therapy for melanoma and clear cell renal cell carcinoma (kidney cancer), which are both frequent FTO-driven cancers.

The Company has compelling clinical data for the use of Zantrene® as a chemotherapeutic agent with reduced cardiotoxicity in Acute Myeloid Leukaemia (AML), Breast and Ovarian cancers and is investigating its use in these areas. Recent discoveries have identified that Zantrene is able to protect the heart muscle from anthracycline-induced damage while being able to synergise to better treat the cancer.

Race is pursuing outsized commercial returns for its shareholders via the ‘Three Pillar’ strategy.

Pipeline

Three Pillar Strategy

We recently presented our updated strategic plans for Race Oncology at our 2021 Annual General Meeting.

Race is led by a seasoned team and Board, supported by a network of key opinion leaders and collaborators. See our leadership team here.

History

2021

Zantrene in the clinic for AML and preclinical programs launched for a range of FTO driven cancers. Zantrene discovered to protect the heart from anthracycline-induced damage while synergising with the chemotherapy drugs to better kill cancer.

2020

Race launches the ‘Three Pillar’ strategy to build on the FTO opportunity.

2019

‘Five Path’ strategy announced advancing Zantrene® in AML, Breast and Ovarian Cancers.

2016

Race Oncology lists on the ASX (RAC) with the mission to rescue Zantrene® and return it to the clinic.

2011-2015

Zantrene® rediscovered by Update Pharma, new patents filed and orphan drug designation obtained.

1990s

Zantrene® was approved for marketing in France for the treatment of AML. Further Zantrene development stopped after issues with the Phase III Breast cancer trial design.

1980s

More than 50 published clinical trials run assess Zantrene’s efficacy and safety in a wide range of cancers including leukemias, breast and ovarian. The studies covered more than 1500 treated patients and revealed that Zantrene® was shown to possess low cardiotoxicity potential and useful therapeutic efficacy in several cancers, notably AML, Breast and Ovarian.

1970s

Zantrene® discovered by the pharmaceutical company Lederle Laboratories.